Acacetin inhibits in vitro and in vivo angiogenesis and downregulates Stat signaling and VEGF expression

Cancer Prevention Research

Volumn 6, Issue 10, 2013, Pages 1128-1139

  Bhat, Tariq A ^a   Nambiar, Dhanya ^a   Tailor, Dhanir ^b   Pal, Arttatrana ^c   Agarwal, Rajesh ^c   Singh, Rana P ^a,b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF GUJARAT   (India)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACACETIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIGEL; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FLAVONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAMININ; MALE; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEOGLYCANS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84887859825     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0209     Document Type: Article

References (46)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74. (Pubitemid 43093963)
2. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87. (Pubitemid 44435320)
3. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 2009;26:51-60.
4. Halvorsen O, Haukaas S, Hoisaeter P, Akslen L. Independent prognostic importance of microvesel density in clinically localized prostate cancer. Anticancer Res 2000;20:3791-99. (Pubitemid 32002277)
5. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999;54:479-85. (Pubitemid 29407025)
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-85.
7. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995;73:497-508.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nat Med 2000;407:249-57.
9. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95. (Pubitemid 30208155)
10. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90. (Pubitemid 37328795)
11. Bhat TA, Singh RP. Tumor angiogenesis - a potential target in cancer chemoprevention. Food Chem Toxicol 2008;46:1334-45. (Pubitemid 351258200)
12. Bhat TA, Moon JS, Lee S, Yim D, Singh RP. Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model. Indian J Exp Biol 2011;49:848-56.
13. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011;2:122-34.
14. Hardin J, Cheng I, Witte JS. Impact of consumption of vegetable, fruit, grain, and high glycemic index foods on aggressive prostate cancer risk. Nutr Cancer 2011;63:860-72.
15. Jansen RJ, Robinson DP, Stolzenberg-Solomon RZ, Bamlet WR, et al. Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Cancer Causes Control 2011;22:1613-25.
16. Wakai K, Matsuo K, Nagata C, Mizoue T, Tanaka K, Tsuji I, et al. Lung cancer risk and consumption of vegetables and fruit: an evaluation based on a systematic review of epidemiological evidence from Japan. Jpn J Clin Oncol 2011;41:693-08.
17. Shu L, Cheung KL, Khor TO, Chen C, Kong AN. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev 2010;29:483-502.
18. Kanadaswami C, Lee LT, Lee PP, Jwang JJ, Ke FC, Huang YT, et al. The antitumor activities of flavonoids. In Vivo 2005;19:895-909.
19. Hsu YL, Kuo PL, Liu CF, Lin CC. Acacetin-induced cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. Cancer Lett 2004;212:53-60.
20. Hsu YL, Kuo PL, Lin CC. Acacetin inhibits the proliferation of Hep G2 by blocking cell cycle progression and inducing apoptosis. Biochem Pharmacol 2004;67:823-29.
21. Singh RP, Agrawal P, Yim D, Agarwal C, Agarwal R. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate. Carcinogenesis 2005;26:845-54. (Pubitemid 41214348)
22. Shim HY, Park JH, Paik HD, Nah SY, Kim DS, Han YS. Acacetin-induced apoptosis of human breast cancer MCF-7 cells involves caspase cascade, mitochondria-mediated death signaling and SAPK/JNK1/2-c-Jun activation. Mol Cells 2007;24:95-04.
23. Shen KH, Hung SH, Yin LT, Huang CS, Chao CH, Liu CL, et al. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol Cell Biochem 2010;333:279-91.
24. Chien ST, Lin SS, Wang CK, Lee YB, Chen KS, Fong Y, et al. Acacetin inhibits the invasion and migration of human non-small cell lung cancer A549 cells by suppressing the p38α MAPK signaling pathway. Mol Cell Biochem 2011;350:135-48.
25. Watanabe K, Kanno S, Tomizawa A, Yomogida S, Ishikawa M. Acacetin induces apoptosis in human T cell leukemia Jurkat cells via activation of a caspase cascade. Oncol Rep 2012;27:204-9.
26. Liu LZ, Jing Y, Jiang LL, Jiang XE, Jiang Y, Rojanasakul Y, et al. Acacetin inhibits VEGF expression, tumor angiogenesis and growth through AKT/HIF-1α pathway. Biochem Biophys Res Commun 2011;413:299-305.
27. Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo - implications for angio-prevention. Carcinogenesis 2012;33:385-93.
28. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032:89-118.
29. Dudley AC, Thomas D, Best J, Jenkins A. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J 2005;390(Pt 2):427-36.
30. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28:185-200. (Pubitemid 351281185)
31. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8. (Pubitemid 34270888)
32. Slomiany MG, Rosenzweig SA. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 2006;318:666-75. (Pubitemid 44061241)
33. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
34. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
35. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-12. (Pubitemid 30070735)
36. Coppé JP, Kauser K, Campisi J, Beauséjour CM. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006;281:29568-74.
37. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54. (Pubitemid 35177340)
38. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14. (Pubitemid 34027945)
39. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4. (Pubitemid 23132159)
40. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9. (Pubitemid 20066716)
41. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
42. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
43. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60. (Pubitemid 43119350)
44. Yang X, Qiao Di, Meyer K, Friedl A. Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res 2009;69:1668-77.
45. Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 2010;126:1777-87.
46. McLesky SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessel independent of the transfected angiogenic factor. Am J Pathol 1998;153:1993-2006. (Pubitemid 28550686)